Molecular Docking: Methodological Approaches of Risk Assessment

Q3 Pharmacology, Toxicology and Pharmaceutics Drug Development and Registration Pub Date : 2023-05-29 DOI:10.33380/2305-2066-2023-12-2-206-210
A. Kh. Taldaev, I. D. Nikitin, R. P. Terekhov, I. A. Selivanova
{"title":"Molecular Docking: Methodological Approaches of Risk Assessment","authors":"A. Kh. Taldaev, I. D. Nikitin, R. P. Terekhov, I. A. Selivanova","doi":"10.33380/2305-2066-2023-12-2-206-210","DOIUrl":null,"url":null,"abstract":"Introduction. Computational chemistry methods and, particularly, the noncovalent molecular docking are increasingly implemented into the practice of drug development. Previously, a risk management of potential biases did not applied for this relatively young research instrument. Aim. The study objective was to design the risk assessment system for noncovalent molecular docking. Materials and methods. The development of bias risk assessment system was based on the world's leading practices in noncovalent molecular docking. Results and discussions. As a result of the deductive analysis of the molecular docking process, bias domains were identified and a risk-based algorithm was proposed, which was tested on a sample of articles obtained during a systematic review. A tendency to frequent limited provision of information on the methodology of the computational experiment, as well as on the application of practices proven to lead to irrelevant results of molecular docking, has been revealed. Conclusion. The data obtained cannot be extrapolated to all studies that refer to the results of molecular modeling. However, through the proposed risk-based algorithm, the attention of researchers is focused on assessing the quality of such publications. We hope that the developed tool for bias risk assessment in noncovalent molecular docking will be finalized and eventually put into practice. It will possibly reduce the share of low-quality work in the field of drug development at the earliest stages.","PeriodicalId":36465,"journal":{"name":"Drug Development and Registration","volume":"5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development and Registration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33380/2305-2066-2023-12-2-206-210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction. Computational chemistry methods and, particularly, the noncovalent molecular docking are increasingly implemented into the practice of drug development. Previously, a risk management of potential biases did not applied for this relatively young research instrument. Aim. The study objective was to design the risk assessment system for noncovalent molecular docking. Materials and methods. The development of bias risk assessment system was based on the world's leading practices in noncovalent molecular docking. Results and discussions. As a result of the deductive analysis of the molecular docking process, bias domains were identified and a risk-based algorithm was proposed, which was tested on a sample of articles obtained during a systematic review. A tendency to frequent limited provision of information on the methodology of the computational experiment, as well as on the application of practices proven to lead to irrelevant results of molecular docking, has been revealed. Conclusion. The data obtained cannot be extrapolated to all studies that refer to the results of molecular modeling. However, through the proposed risk-based algorithm, the attention of researchers is focused on assessing the quality of such publications. We hope that the developed tool for bias risk assessment in noncovalent molecular docking will be finalized and eventually put into practice. It will possibly reduce the share of low-quality work in the field of drug development at the earliest stages.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
分子对接:风险评估的方法论方法
介绍。计算化学方法,特别是非共价分子对接越来越多地应用于药物开发实践。以前,潜在偏差的风险管理并没有应用于这个相对年轻的研究工具。的目标。本研究的目的是设计非共价分子对接的风险评估系统。材料和方法。偏置风险评估系统的开发是基于非共价分子对接的国际领先实践。结果和讨论。通过对分子对接过程的演绎分析,确定了偏置域,提出了一种基于风险的算法,并在系统综述中获得的文章样本上进行了测试。已经揭示了一种趋势,即经常有限地提供关于计算实验方法的信息,以及关于被证明导致分子对接无关结果的实践的应用。结论。所获得的数据不能外推到所有涉及分子模拟结果的研究。然而,通过提出的基于风险的算法,研究人员的注意力集中在评估此类出版物的质量上。我们希望开发的非共价分子对接偏倚风险评估工具能够最终定型并投入实际应用。它可能会在药物开发领域的早期阶段减少低质量工作的份额。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug Development and Registration
Drug Development and Registration Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
1.20
自引率
0.00%
发文量
61
审稿时长
8 weeks
期刊最新文献
Medicinal Perspectives of Retinoids (Review) End-to-end Standardization of Original Medicines when Determining Related Impurities Development of Amlodipine Mini-tablets as a Polypill-component for the Personalized Therapy of Arterial Hypertension Composition and Technology Development for Obtaining Amorphous Solid Dispersion of Ebastine by Hot Melt Extrusion to Increase Dissolution Rate Could Bioluminescent Bacteria be Used in the Search for New Plant-derived Antibacterial Substances?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1